Varanasi News Magazine

DelveInsight Business Research LLP

DelveInsight’s “Uncomplicated Urinary Tract Infection Market Insights, Epidemiology, and Market Forecast-2032“ report delivers an in-depth understanding of the Uncomplicated Urinary Tract Infection, historical and forecasted epidemiology as well as the Uncomplicated Urinary Tract Infection () market trends in the United States, EU4 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.

 Uncomplicated Urinary Tract Infection Overview

Urinary tract infection is the most common bacterial infection caused by a range of pathogens, but most commonly by Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Enterococcus faecalis, and Staphylococcus saprophyticus.

A urinary tract infection can develop in any part of the urinary tract, including the urethra, bladder, ureters, or kidneys. They are classified as either complicated or uncomplicated.

Uncomplicated urinary tract infections typically affect individuals who are otherwise healthy and have no structural or neurological urinary tract abnormalities. Complicated urinary tract infection is associated with factors that compromise the urinary tract or host defense.

Uncomplicated Urinary Tract Infection Epidemiology Insights

• As per Tandogdu and Wagenlehner’s (2016) study, the prevalence of healthcare-associated infection is 4% in the US and 6% in Europe. And the frequency of HAUTI among healthcare-associated infections is 12.9%, 19.6%, and 24% in the United States, Europe, and developing countries, respectively.

• According to Kranz et al. (2017), uncomplicated bacterial urinary tract infection is one of the most commonly occurring community-acquired infections. In 2013, 7.32% of the female members of the German health insurance fund Barmer GEK were diagnosed with uncomplicated urinary tract infection, 1.73% with acute uncomplicated cystitis, and 0.16% with acute uncomplicated pyelonephritis.

• According to a survey study by Butler et al. (2015), in England, 37% of females surveyed reported a urinary tract infection at some point in their lifetime, and 28% reported more than one urinary tract infection episode.

• Approximately 75–80% of uncomplicated urinary tract infection cases are Uropathogenic Escherichia coli (E. coli) UPEC pathogen-specific cases. UPEC is the dominant infectious agent in both uncomplicated and complicated UTI. Infection with UPEC increases the likelihood of recurrence within 6 months. Etiology in older postmenopausal women varies depending on their health status, residential status (institutionalized or not), age, the presence of diabetes mellitus, history of/current catheterization, spinal cord dysfunction, and history of antibiotic use. Most UTIs in non-catheterized older adults are caused by a single bacterial species.

Click here to learn more about the Uncomplicated Urinary Tract Infection Market Landscape

The Report Covers the Uncomplicated Urinary Tract Infection Epidemiology Segmented by:

• Total Uncomplicated Urinary Tract Infection occurrence specific cases 

• Total Uncomplicated Urinary Tract Infection diagnosed cases 

• Total Uncomplicated Urinary Tract Infection age-specific cases 

• Total Uncomplicated Urinary Tract Infection pathogen-specific cases 

Uncomplicated Urinary Tract Infection Market Outlook 

The Uncomplicated Urinary Tract Infection market outlook of the report helps to build a detailed comprehension of the historic, current, and forecasted Uncomplicated Urinary Tract Infection market trends by analyzing the impact of current therapies on the market, unmet needs, drivers, and barriers and demand of better technology.

This segment gives a thorough detail of the Uncomplicated Urinary Tract Infection market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion, and exclusion criteria, mechanism of action, compliance rate, growing need for the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the Uncomplicated Urinary Tract Infection market in 7MM is expected to witness a major change in the study period 2019-2032.

 Key Companies Working in the Uncomplicated Urinary Tract Infection Market

• GlaxoSmithKline

• Iterium Therapeutics 

• Inmunoteck

• Janssen Pharmaceuticals  

• Fimbrion Therapeutics 

And many others 

Uncomplicated Urinary Tract Infection Therapies Covered and Analyzed in the Report:

• Gepotidacin

• GSK3882347

• Sulopenem

• Phenazopyridine Hydrochloride

• PP4001

And many others 

Learn more about the Key Companies and Emerging Therapies in the Uncomplicated Urinary Tract Infection Market

Table of Contents 

1. Key Insights 

2. Uncomplicated Urinary Tract Infection Introduction 

3. Executive Summary of Uncomplicated Urinary Tract Infection  

4. Disease Background and Overview

5. Epidemiology and patient population

6. Uncomplicated Urinary Tract Infection Emerging Therapies

7. Uncomplicated Urinary Tract Infection Market Outlook

8. Market Access and Reimbursement of Therapies

9. Market Drivers 

10. Market Barriers 

11. Appendix

12. Report Methodology

13. DelveInsight Capabilities

14. Disclaimer

Learn about the detailed offerings of the report @ Uncomplicated Urinary Tract Infection Market Outlook 

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Adya Kaul
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services